Home > Publications database > Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. > print

001     141401
005     20240229112524.0
024 7 _ |a 10.1038/s41375-018-0195-9
|2 doi
024 7 _ |a pmid:29959413
|2 pmid
024 7 _ |a 0887-6924
|2 ISSN
024 7 _ |a 1476-5551
|2 ISSN
024 7 _ |a altmetric:44324965
|2 altmetric
037 _ _ |a DKFZ-2018-01907
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Mai, Elias K
|0 0000-0002-6226-1252
|b 0
245 _ _ |a Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.
260 _ _ |a London
|c 2019
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1550215815_21966
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 1
|u dkfz
700 1 _ |a Bertsch, Uta
|b 2
700 1 _ |a Schlenzka, Jana
|b 3
700 1 _ |a Salwender, Hans J
|b 4
700 1 _ |a Munder, Markus
|b 5
700 1 _ |a Gerecke, Christian
|b 6
700 1 _ |a Dührsen, Ulrich
|b 7
700 1 _ |a Brossart, Peter
|b 8
700 1 _ |a Neben, Kai
|b 9
700 1 _ |a Hillengass, Jens
|b 10
700 1 _ |a Raab, Marc S
|b 11
700 1 _ |a Merz, Maximilian
|b 12
700 1 _ |a Baertsch, Marc-Andrea
|b 13
700 1 _ |a Jauch, Anna
|b 14
700 1 _ |a Hose, Dirk
|b 15
700 1 _ |a Martin, Hans
|b 16
700 1 _ |a Lindemann, Hans-Walter
|b 17
700 1 _ |a Blau, Igor W
|b 18
700 1 _ |a Scheid, Christof
|b 19
700 1 _ |a Weisel, Katja C
|b 20
700 1 _ |a Goldschmidt, Hartmut
|b 21
700 1 _ |a Group, German-speaking Myeloma Multicenter
|b 22
|e Collaboration Author
773 _ _ |a 10.1038/s41375-018-0195-9
|0 PERI:(DE-600)2008023-2
|n 1
|p 258-261
|t Leukemia
|v 33
|y 2019
|x 1476-5551
909 C O |o oai:inrepo02.dkfz.de:141401
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LEUKEMIA : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b LEUKEMIA : 2017
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21